Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)

Inclusion Criteria: * Newly diagnosed T2DM and inadequately controlled with diet and exercise or T2DM diagnosed \<6 months and who had not taken oral antidiabetic medication or insulin for \>3months. * HbA1C more than 7.5 and less than 11. Exclusion Criteria: * Fasting plasma glucose of \>13.5mmol/L * Type 1 Diabetes Mellitus (T1DM) * Patient with acute illness hospitalized in last 2 months * Patient with active liver disease, impaired renal or hepatic functions * Known hypersensitivity to glimepiride, other sulfonylureas, other sulfonamides or any other excipients of AMARYL * Pregnant and lactating women The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.